SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB
SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB
复制标题
DOI：
10.1097/iae.0b013e318217ffde
复制
发表时间：
2011-06-01
影响因子：
3.3
通讯作者：
Gorin, Michael B.
中科院分区：
文献类型：
--
作者：
Choi, Daniel Y.;Ortube, Maria Carolina;Gorin, Michael B.
目的：研究玻璃体内注射抗血管内皮生长因子治疗老年性黄斑变性后眼内压（IOP）升高（随访时测量bbb25 mmHg）。方法：回顾性分析医疗记录。结果：共有127名患者（155只眼睛）接受了玻璃体内注射抗血管内皮生长因子药物（贝伐单抗、雷尼单抗或佩加他尼），注射次数从1到39次不等，持续时间超过30到1759天。在该人群中，12例患者（14只眼，9.4%）IOP升高至25mmhg。其中，7名患者（5.5%）出现持续的IOP升高（两次单独就诊时IOP低于25 mmHg，需要青光眼药物治疗或手术），其中8只眼睛需要局部药物治疗，1只眼睛进行了青光眼手术。玻璃体内注射组平均IOP为15.2 +/- 2.4 mmHg，未注射组平均IOP为14.9 +/- 2.6 mmHg。在IOPs升高的眼睛中，与注射频率、注射次数或使用抗血管内皮生长因子无关。结论：玻璃体内注射后IOP持续或不持续升高并不罕见。在作者的研究人群中，没有发现与患者人口统计学或注射史有关。视网膜31:28 -1035,2011
Purpose: To investigate elevated intraocular pressures (IOP) (defined by a measurement >25 mmHg at a follow-up visit) after an intravitreal injection of anti-vascular endothelial growth factor agents for age-related macular degeneration.Methods: Retrospective review of medical records.Results: A total of 127 patients (155 eyes) received an intravitreal injection of antivascular endothelial growth factor agents (bevacizumab, ranibizumab, or pegaptanib) ranging from 1 to 39 injections for more than a period of 30 to 1759 days. Among this population, 12 patients (14 eyes; 9.4%) developed elevated IOP >25 mmHg. Of these, 7 patients (5.5%) developed sustained elevated IOP (IOP >25 mmHg on 2 separate visits requiring glaucoma medication or surgery), of which 8 eyes required topical medications and 1 eye underwent glaucoma surgery. Mean IOP of injected eyes receiving intravitreal injection was 15.2 +/- 2.4 mmHg, and the mean IOP was 14.9 +/- 2.6 mmHg for noninjected eyes. Among eyes that had elevated IOPs, there was no association with injection frequency, number of injections, or anti-vascular endothelial growth factor agent used.Conclusion: Elevated IOP, sustained or unsustained, after intravitreal injection is not uncommon. No association with patient demographics or injection history was identified in the authors' study population. RETINA 31:1028-1035, 2011